Free Trial

Enliven Therapeutics (ELVN) 10K Form and Latest SEC Filings 2026

Enliven Therapeutics logo
$41.13 -0.45 (-1.08%)
As of 12:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Enliven Therapeutics SEC Filings & Recent Activity

Enliven Therapeutics (NASDAQ:ELVN) has submitted 545+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Enliven Therapeutics's financial statements. The most recent filing was a Form 144 submitted on April 30, 2026.

Form 4
Enliven Therapeutics, Inc. Reports Ownership Change on Apr. 21, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Enliven Therapeutics Files Quarterly Report on Nov. 13, 2024

The 10-Q contains Enliven Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Enliven Therapeutics SEC Filing History

Browse Enliven Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/30/2026 3:17 PM
Enliven Therapeutics (1672619) Subject
Lyssikatos Joseph P (1967150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 3:06 PM
Enliven Therapeutics (1672619) Filer
Form DEF 14A
04/21/2026 7:40 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:06 PM
Enliven Therapeutics (1672619) Filer
Form PRE 14A
03/27/2026 3:57 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 3:29 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/24/2026 3:26 PM
Enliven Therapeutics (1672619) Subject
Patel Anish (1967163) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/19/2026 4:50 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 4:32 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 5:15 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 3:12 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2026 3:06 PM
Enliven Therapeutics (1672619) Subject
Hohl Benjamin (1882764) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2026 4:21 PM
Enliven Therapeutics (1672619) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/03/2026 3:10 PM
Enliven Therapeutics (1672619) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/19/2026 5:36 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 5:38 PM
Enliven Therapeutics (1672619) Issuer
Heyman Richard A. (1584759) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:47 PM
Collins Helen Louise (1701247) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:49 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:52 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:53 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:55 PM
Ballal Rahul D. (1805097) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:56 PM
Bauer Jake (1654909) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:56 PM
Derynck Mika K (1865125) Reporting
Enliven Therapeutics (1672619) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:57 PM
Enliven Therapeutics (1672619) Issuer
Garland J. Scott (1533228) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:59 PM
Enliven Therapeutics (1672619) Issuer
Gupta Rishi (1537370) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:00 PM
Enliven Therapeutics (1672619) Issuer
Heyman Richard A. (1584759) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:01 PM
Enliven Therapeutics (1672619) Issuer
Kunkel Lori Anne (1536368) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 5:12 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 4:38 PM
Enliven Therapeutics (1672619) Subject
Phillips Andrew John (1921956) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2026 4:34 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 4:33 PM
Enliven Therapeutics (1672619) Issuer
Heyman Richard A. (1584759) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 4:54 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:11 PM
Enliven Therapeutics (1672619) Issuer
Heyman Richard A. (1584759) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:12 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 5:04 PM
Enliven Therapeutics (1672619) Issuer
Garland J. Scott (1533228) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/09/2026 5:10 PM
Enliven Therapeutics (1672619) Issuer
Garland J. Scott (1533228) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 3:49 PM
Enliven Therapeutics (1672619) Subject
Kintz Samuel (1967168) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 3:50 PM
Enliven Therapeutics (1672619) Subject
Lyssikatos Joseph P (1967150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 3:18 PM
Enliven Therapeutics (1672619) Subject
Patel Anish (1967163) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:42 PM
Enliven Therapeutics (1672619) Subject
Kintz Samuel (1967168) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:18 PM
Enliven Therapeutics (1672619) Subject
Heyman Richard A. (1584759) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:26 PM
Enliven Therapeutics (1672619) Subject
Heyman Richard A. (1584759) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:26 PM
Enliven Therapeutics (1672619) Subject
Lyssikatos Joseph P (1967150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2026 8:15 AM
Enliven Therapeutics (1672619) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/23/2025 5:45 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 5:47 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 4:58 PM
Enliven Therapeutics (1672619) Issuer
Kunkel Lori Anne (1536368) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:32 PM
Enliven Therapeutics (1672619) Subject
Lyssikatos Joseph P (1967150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2025 3:23 PM
Enliven Therapeutics (1672619) Subject
Kintz Samuel (1967168) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2025 3:14 PM
Enliven Therapeutics (1672619) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/12/2025 5:30 PM
Enliven Therapeutics (1672619) Issuer
Fair Richard A. (1695851) Reporting
Form 3
Initial statement of beneficial ownership of securities  
12/12/2025 5:31 PM
Enliven Therapeutics (1672619) Issuer
Fair Richard A. (1695851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 8:11 AM
Enliven Therapeutics (1672619) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2025 4:13 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 3:18 PM
Enliven Therapeutics (1672619) Subject
Patel Anish (1967163) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2025 4:28 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 5:45 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:05 PM
Enliven Therapeutics (1672619) Subject
Lyssikatos Joseph P (1967150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/17/2025 3:16 PM
Enliven Therapeutics (1672619) Subject
Kintz Samuel (1967168) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2025 4:32 PM
Enliven Therapeutics (1672619) Subject
Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by
Form SCHEDULE 13G/A
11/12/2025 8:58 PM
Enliven Therapeutics (1672619) Filer
Form 8-K/A
11/12/2025 4:34 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 3:10 PM
Enliven Therapeutics (1672619) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2025 10:35 AM
Enliven Therapeutics (1672619) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G/A
10/22/2025 6:20 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/21/2025 5:13 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2025 3:16 PM
Enliven Therapeutics (1672619) Subject
Kintz Samuel (1967168) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/09/2025 4:21 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 3:46 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2025 4:51 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2025 4:53 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 4:19 PM
Enliven Therapeutics (1672619) Subject
Hohl Benjamin (1882764) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/25/2025 6:42 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2025 6:44 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:14 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2025 6:12 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2025 4:32 PM
Enliven Therapeutics (1672619) Subject
Lyssikatos Joseph P (1967150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2025 7:12 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2025 3:30 PM
Enliven Therapeutics (1672619) Subject
Patel Anish (1967163) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/29/2025 4:03 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 3:44 PM
Enliven Therapeutics (1672619) Subject
Hohl Benjamin (1882764) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/21/2025 5:46 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 5:48 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4/A
08/20/2025 3:36 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 4:06 PM
Commodore Capital LP (1831942) Filed by
Enliven Therapeutics (1672619) Subject
Form SCHEDULE 13G/A
08/14/2025 7:01 AM
Enliven Therapeutics (1672619) Subject
Polar Capital Holdings Plc (1837309) Filed by
Form SCHEDULE 13G
08/11/2025 5:51 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2025 4:57 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/23/2025 5:52 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/21/2025 6:21 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2025 6:54 PM
BlackRock, Inc. (2012383) Filed by
Enliven Therapeutics (1672619) Subject
Form SCHEDULE 13G/A
07/17/2025 3:13 PM
Enliven Therapeutics (1672619) Subject
Kintz Samuel (1967168) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/14/2025 4:07 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2025 6:29 PM
Enliven Therapeutics (1672619) Issuer
Patel Anish (1967163) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/07/2025 3:15 PM
Enliven Therapeutics (1672619) Subject
Patel Anish (1967163) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/01/2025 3:42 PM
Enliven Therapeutics (1672619) Issuer
Hohl Benjamin (1882764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 3:05 PM
Enliven Therapeutics (1672619) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025 4:36 PM
Enliven Therapeutics (1672619) Issuer
Lyssikatos Joseph P (1967150) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 5:22 PM
Enliven Therapeutics (1672619) Issuer
Kintz Samuel (1967168) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 4:30 PM
Enliven Therapeutics (1672619) Subject
ORBIMED ADVISORS LLC (1055951) Filed by
Form SCHEDULE 13D/A
(Data available from 1/1/2016 forward)

Enliven Therapeutics SEC Filings - Frequently Asked Questions

Enliven Therapeutics (ELVN) has submitted 545+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Enliven Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Enliven Therapeutics's financial statements page.

The most recent filing was a Form 144 submitted on April 30, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners